Press Room

New EU Patent provides ViroGates access to the multibillion USD market for prediction of Cardiovascular Disease

Denmark, October 25, 2013

ViroGates has received notification from the European Patent Office that Patent application 07858108.9 Solubleurokinase plasminogen activator receptor (suPAR) as predictive marker for cardiovascular disease will be granted. The Patent will be subject to national filing in the European countries, and will allow ViroGates protection of use of its suPARnostic® product range in the testing of healthy individuals to determine risk of development of cardiovascular disease, which is a leading cause of death worldwide.